Exploration of target molecules for prostate cancer gene therapy

Prostate

Volumn 67, Issue 11, 2007, Pages 1163-1173

  Suzuki, Kazuhiro ^a   Nakamura, Kiminori ^a   Kato, Kazunori ^a   Hamada, Hirofumi ^a   Tsukamoto, Taiji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gene therapy; Modified adenovirus vector; Monoclonal antibody; Prostate cancer

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOVIRUS VECTOR; ANTIGEN; ANTIGEN HAI 1; CD155 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BINDING SITES, ANTIBODY; CELL ADHESION MOLECULES; CELL LINE, TUMOR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN G; MALE; MICE; PROSTATIC NEOPLASMS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; STAPHYLOCOCCAL PROTEIN A; VIRAL PROTEINS;

EID: 34547664737     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20613     Document Type: Article

References (32)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002;52:23-47.
2. Kasper S, Cookson MS. Mechanism leading to the development of hormone-resistant prostate cancer. Urol Clin N Am 2006;33: 201-210.
3. Macrae EJ, Giannoudis A, Ryan R, Brown NJ, Hamdy FC, Maitland N, Lewis CE. Gene therapy for prostate cancer: Current strategies and new cell-based approaches. Prostate 2006;66:470-494.
4. Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann N Y Acad Sci 1994;716:90-101; (discussion 101-103).
5. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-1323.
6. Volpers C, Thirion C, Biermann V, Hussmann S, Kewes H, Dunant P, von der Mark H, Herrmann A, Kochanek S, Lochmuller H. Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J Virol 2003;77:2093-2104.
7. Hisataki T, Itoh N, Suzuki K, Takahashi A, Masumori N, Tohse N, Ohmori Y, Yamada S, Tsukamoto T. Modulation of phenotype of human prostatic stromal cells by transforming growth factor-betas. Prostate 2004;58:174-182.
8. Tanaka T, Huang J, Hirai S, Kuroki M, Kuroki M, Watanabe N, Tomihara K, Kato K, Hamada H. Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res 2006;12: 3803-3813.
9. Kitamura H, Torigoe T, Asanuma H, Hisasue SI, Suzuki K, Tsukamoto T, Satoh M, Sato N. Cytosolic overexpression of p62 sequestosome 1 in neoplastic: prostate tissue. Histopathology 2006;48:157-161.
10. Getzenberg RH, Abrahamsson PA, Canto EI, Chinnaiyan AM, Djavan B, Laxman B, Ogawa O, Slawin K, Tomlins SA, Yu J. Advances in biomarkers for prostatic disease. In: McConnell J, Denis L, Akaza H, Khoury S, Schalken J, editors. Prostate Cancer. Paris: Health Publications; 2006. pp 85-148.
11. Lieberman R. Evidence-based medical perspectives: The evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther 2004;11:501-506.
12. Migita T, Oda Y, Naito S, Morikawa W, Kuwano M, Tsuneyoshi M. The accumulation of angiostatin-like fragments in human prostate carcinoma. Clin Cancer Res 2001;7:2750-2756.
13. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-935.
14. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54: 1807-1811.
15. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate 2000;43:150-157.
16. Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, Schulman CC. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC-3 models of the human prostate. Cancer 1996;77:144-149.
17. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000;60:5031-5036.
18. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76:1438-1442.
19. Momburg F, Moldenhauer G, Hammerling GJ, Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883-2891.
20. Xie X, Wang CY, Cao YX, Wang W, Zhuang R, Chen LH, Dang NN, Fang L, Jin BQ. Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol 2005;11:344-347.
21. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006;94: 128-135.
22. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien PM. Overexpression of the cell adhesion molecules DDR1, claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004;10:4427-4436.
23. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999; 162:1462-1466.
24. Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: A review of clinical trials. Expert Rev Vaccines 2005;4:329-350.
25. Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, Locher M, Prang N, Baeuerle PA, Leo E. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer 2006;42:2530-2538.
26. Heideman DA, Snijders PJ, Craanen ME, Bloemena E, Meijer CJ, Meuwissen SG, van Beusechem VW, Pinedo HM, Curiel DT, Haisma HJ, Gerritsen WR. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 2001;8:342-351.
27. Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997;272:6370-6376.
28. Kataoka H, Suganuma T, Shimomura T, Itoh H, Kitamura N, Nabeshima K, Koono M. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem 1999;47:673-682.
29. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, Dickson RB, Lin CY. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001;158:1301-1311.
30. Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol 2005;167:255-266.
31. Nagakawa O, Yamagishi T, Akashi T, Nagaike K, Fuse H. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Prostate 2006;66:447-452.
32. Lampe MI, Molkenboer-Kuenen JD, Oosterwijk E. Development of new prostate specific monoclonal antibodies. Prostate 2004; 58:225-231.